Mrs. Sarah J. Yusuf, Nigeria
Mycophenolate mofetil and the incidence of skin cancer in kidney transplant recipients
Mr. John T Black, United Kingdom
The incidence of glucose impairment and new onset diabetes (NODAT) after renal transplant: A retrospective 12-month review at a single UK-centre.
Dr. Malek Mojaat, Tunisia
Management of peripheral facial palsy in kidney transplant patients: A case series
Mladen Knotek, Croatia
Intensified vs. standard mycophenolate dosing during the first year after kidney transplantation
Dr. Samy M Riad, United States
Pediatric primary deceased-donor-kidney transplant-recipients outcomes by immunosuppression induction received in the United States
Dr. Samy M Riad, United States
Pediatric primary live-donor-kidney transplant-recipients outcomes by immunosuppression induction received in the United States
Christian Unterrainer, Germany
Once- versus twice-daily tacrolimus and graft survival
Dr. Swapneel Anaokar, United Kingdom
Global, multicentre, non-interventional study to assess long-term outcomes in kidney transplant recipients converting from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus: 4-year interim analysis of the CHORUS study
Dr. Swapneel Anaokar, United Kingdom
Long-term outcomes in kidney transplant recipients converting from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus in Asian countries: 3-year interim analysis of the multicentre, non-interventional CHORUS study
Dr. Yoshihiko Watarai, Japan
Efficacy and safety of everolimus with reduced calcineurin inhibitor regimen versus mycophenolic acid with standard calcineurin regimen in Asian de novo kidney transplant recipients: Two-year results from the subgroup analysis of TRANSFORM study
Shigeyoshi Yamanaga, Japan
Two year outcomes of low-dose vs very low-dose extended-release tacrolimus / mycophenolate mofetil in de novo kidney transplantation: A multi-center randomized controlled trial
Dr. Avinash R Odugoudar, United Kingdom
Comparison of single-dose vs double dose Alemtuzumab in renal transplant recipients: A single centre experience
Dr. Osama Gheith, Kuwait
Kidney re-transplant: Single-center experience from MENA region
Prof. Michael Kaabak, Russian Federation
Unusual approach to assess induction therapy efficacy in kidney transplantation
Dr. Maisarah Jalalonmuhali, Malaysia
Single centre experience on ultra low dose Thymoglobulin as an induction agent in low immunological risk living kidney transplant recipients
Sung Shin, Korea
Low dose (4.5 mg/kg) of Thymoglobulin is effective to control T cells but not B cells and CD56dimCD57+, CD56dimNKG2A+ natural killer cells resulting in de novo donor-specific antibody formation and acute rejection in non-sensitized living donor kidney recipients with early steroid withdrawal
Ms. Pei Wen Ong, Singapore
Impact on short-term outcomes from a switch from a Cyclosporine-based to Tacrolimus-based immunosuppression protocol for kidney transplantation in an Asian transplant centre
Dr. Jun Bae Bang, Korea
Clinical study of standard- versus reduced-dose tacrolimus combined with generic mycophenolate mofetil in de novo kidney transplantation: A prospective randomized trial
Mr. HAO XING, People's Republic of China
Effects of immunosuppression and adjuvant immune-targeted drugs in preventing HCC recurrence after liver transplantation
Dr. CRISTINA DOPAZO, Spain
High intrapatient variability of tacrolimus exposure after liver transplantation as new marker of poor outcomes
Dr. Kin Pan Au, Hong Kong
Mammalian target of rapamycin Inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?
Duck Jong Han, Korea
Efficacy and safety of everolimus with reduced-exposure cyclosporine in de novo kidney transplant recipients: 24-month post-hoc analysis from the TRANSFORM study
Prof. Julio Pascual, Spain
Analysis of Immunobiogram pharmacodynamic dose-response curves to immunosuppressants in kidney transplant recipients: Further results from Transbio Study
Dr. Kanitha Tiankanon, Thailand
Milligram to milligram conversion of twice daily to once daily tacrolimus provides equivalent drug exposure in adult kidney transplant
Prof. Tian Puxun, People's Republic of China
The feature of MDSCs in the long-term stable kidney transplant recipients after different immunosuppression therapy
Björn Nashan, Germany
Athena vs Hephaistos - Are discontinuation rates in multicenter studies driven by facts or attitudes?
Maria Simonenko, Russian Federation
Outcomes of everolimus after heart transplantation
Man Ki Ju, Korea
Efficacy and safety of everolimus in Korean kidney transplant recipients: Results from a prospective, open label, multicenter, single arm trial
Natalia Riva, Argentina
Feasibility of steroid-free tacrolimus-basiliximab immunosuppression in pediatric liver transplantation
Dr. Yoko Watanabe, Japan
Safety and efficacy of everolimus in maintenance kidney transplant patients: A 2-year post-marketing surveillance study in Japan
